Current concepts in the diagnosis and management of cytokine release syndrome

• Published in: Blood Vol. 124; no. 2; pp. 188 - 195
• Main Authors: Lee, Daniel W., Gardner, Rebecca, Porter, David L., Louis, Chrystal U., Ahmed, Nabil, Jensen, Michael, Grupp, Stephan A., Mackall, Crystal L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 10.07.2014; American Society of Hematology
• Subjects: Child; Cytokines - metabolism; Female; How I Treat; Humans; Immune System Diseases - diagnosis; Immune System Diseases - metabolism; Immune System Diseases - therapy; Leukemia - diagnosis; Leukemia - immunology; Leukemia - metabolism; Leukemia - therapy; Paraneoplastic Syndromes - diagnosis; Paraneoplastic Syndromes - metabolism; Paraneoplastic Syndromes - therapy; Young Adult
• ISSN: 0006-4971; 1528-0020; 1528-0020
• DOI: 10.1182/blood-2014-05-552729

As immune-based therapies for cancer become potent, more effective, and more widely available, optimal management of their unique toxicities becomes increasingly important. Cytokine release syndrome (CRS) is a potentially life-threatening toxicity that has been observed following administration of natural and bispecific antibodies and, more recently, following adoptive T-cell therapies for cancer. CRS is associated with elevated circulating levels of several cytokines including interleukin (IL)-6 and interferon γ, and uncontrolled studies demonstrate that immunosuppression using tocilizumab, an anti-IL-6 receptor antibody, with or without corticosteroids, can reverse the syndrome. However, because early and aggressive immunosuppression could limit the efficacy of the immunotherapy, current approaches seek to limit administration of immunosuppressive therapy to patients at risk for life-threatening consequences of the syndrome. This report presents a novel system to grade the severity of CRS in individual patients and a treatment algorithm for management of CRS based on severity. The goal of our approach is to maximize the chance for therapeutic benefit from the immunotherapy while minimizing the risk for life threatening complications of CRS.